GE HealthCare’s MIM Software, a global leader in medical imaging analysis and AI solutions, introduces MIM Symphony HDR Prostate, designed to support high dose-rate (HDR) brachytherapy. This innovative tool aims to enhance clinician confidence and improve patient outcomes by providing direct tumor visualization from MRI scans during live ultrasound procedures for HDR prostate treatments.
MIM Symphony HDR Prostate distinguishes itself by correcting MRI orientation and offering MRI guidance during HDR prostate procedures. HDR brachytherapy, a prostate cancer treatment, involves implanting radioactive sources into the prostate gland via needles. Traditionally, clinicians use CT or ultrasound imaging for planning these procedures. Incorporating MRI into brachytherapy planning can reduce toxicity to critical structures. However, accurately aligning MRI contours with live ultrasound images has been challenging, limiting MRI use in HDR treatments.
Dr. Peter Rossi, Chairman of the Board at the American Brachytherapy Society and Radiation Oncologist at Valley View Hospital, stated, “MRI guidance enables more confident, precise treatments and reduces toxicity to organs at risk. I’ve had the pleasure of providing my patients with precise treatments using MRI guidance in MIM Symphony HDR Prostate and look forward to other clinics having the same opportunity.”
GE HealthCare’s MIM Software developed MIM Symphony HDR Prostate to align contours on preoperative MRI with live ultrasound, offering clear visibility of the prostate, lesions, and critical structures during HDR procedures. Aligning the MRI contours with the ultrasound assists clinicians in precise needle placement by:
- Defining the lesion and tracking changes to guide needle placement as the prostate moves during the procedure
- Correcting differences between MRI supine and ultrasound lithotomy orientations with ReSlicer, a tool in MIM Symphony HDR Prostate
- Automatically digitizing needles on CT or ultrasound planning images, performing needle review, and free length checks
“Our goal is to empower clinicians to plan and deliver safe, informed, and precise treatments for patients with prostate disease,” said Andrew Nelson, CEO of MIM Software, GE HealthCare. “MIM Symphony HDR Prostate exemplifies decades of innovation from MIM Software and GE HealthCare, and we’re thrilled to expand our impact in brachytherapy.”
This new solution is the latest addition to GE HealthCare’s MIM Software portfolio of vendor-neutral solutions for radiation oncology. Following the acquisition of MIM Software’s portfolio, including MIM Maestro, Contour ProtégéAI+, and MIM Symphony LDR, GE HealthCare continues to offer a broad range of solutions across precision imaging and radiopharmaceuticals, enhancing efficiency and optimizing care across care pathways.
Visit MIMSoftware.com for more information on MIM Symphony HDR Prostate and GEHealthCare.com for details on additional radiation oncology offerings. MIM Symphony HDR Prostate will be showcased at upcoming global conferences.
